NCT01717846: Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis |
|
|
| Withdrawn | 4 | 0 | US | Group 1 or Orencia treated group, Abatacept, Group 2 (DMARDS treated group), Arm 2 or group 2 | University of California, Los Angeles, Bristol-Myers Squibb | Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis | 11/13 | 11/14 | | |
A-BREAK, NCT01846975: Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday |
|
|
| Completed | 4 | 49 | Europe | IV Abatacept, Switch from SC to IV Abatacept and back | Rüdiger B. Müller, Bristol-Myers Squibb | Rheumatoid Arthritis | 12/14 | 01/15 | | |
NCT01758198: Abatacept Post-marketing Clinical Study in Japan |
|
|
| Completed | 4 | 405 | Japan | Abatacept, BMS-188667 (Orencia), Placebo matching with Abatacept, Methotrexate | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Rheumatoid Arthritis | 12/16 | 12/16 | | |
